Alexa Fluor® 568 Anti-CD7 antibody [EPR4242],Abcam,AB312617
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
Host
Rabbit
Reactivity
Human, Mouse, Rat
Application
Flow Cyt (Intra), Target Binding Affinity, Antibody Labelling, ICC/IF, IHC-P
Conjugate
Alexa Fluor® 568
Platform ID
BAB732893773
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Transmembrane glycoprotein expressed by T-cells and natural killer (NK) cells and their precursors (PubMed : 7506726). Plays a costimulatory role in T-cell activation upon binding to its ligand K12/SECTM1 (PubMed : 10652336). In turn, mediates the production of cytokines such as IL-2 (PubMed : 1709867). On resting NK-cells, CD7 activation results in a significant induction of interferon-gamma levels (PubMed : 7506726). See full target information CD7
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.